Is Lila Sciences profitable in 2026?

Lila Sciences discloses no revenue figures. As of October 2025 it had raised $550M total and was valued above $1.3B, and it says it began onboarding an undisclosed first cohort of commercial partners that month, but no paying customers have been named as of July 2026.

Who owns Lila Sciences?

Lila Sciences is privately held, founded in 2023 inside Flagship Pioneering, the venture-creation firm behind Moderna, which remains an investor. It publicly unveiled from stealth on March 10, 2025 with a $200M seed round led by Flagship Pioneering.

Could AI replace what Lila Sciences does?

Lila Sciences is itself the AI disruptor, not a target: its business model bets that AI agents plus robotic labs can replace human-driven hypothesis generation and experimentation, a shift it calls a 'Deep Blue moment' for science, per its own June 2026 team commentary.

Is joining Lila Sciences a safe career move?

Lila Sciences has raised $550M as of October 2025 at a valuation above $1.3B and was reportedly in talks for a ~$2B Series B as of June 3, 2026, but it has no named customers, no confirmed revenue, and its flagship factory is still targeted to open Q3 2026, making it a high-upside, high-uncertainty bet.

Who is Lila Sciences' biggest competitor?

Lila Sciences faces well-funded rivals running near-identical playbooks: Periodic Labs, founded by ex-OpenAI and DeepMind researchers, had raised $605M as of June 11, 2026, while Isomorphic Labs (Alphabet/DeepMind) and Ginkgo Bioworks compete in adjacent autonomous-lab and drug-discovery models.

Has Lila Sciences raised a Series B?

As of June 3, 2026, Bloomberg reported Lila Sciences was in talks for a roughly $2B Series B anchored by CalPERS and Nvidia's NVentures at about $8.5B pre-money valuation, but terms were not final and no primary Lila press release confirming a closed round existed as of July 29, 2026.

United States · United States

Lila Sciences

Builds robotic AI labs to automate scientific discovery for drugs and materials, pre-revenue.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: 200,000 sq ft AI Science Factory in Cambridge targeted to open

The call

Lila has the money and the pedigree to build an AI-run lab, but no factory running, no named customer, and no published result yet separates the story from the science.

Lila Sciences is building robot labs to generate data that trains AI to discover new drugs and materials. The company claims its private robot data gives it an edge competitors cannot easily copy, but that edge exists only as a promise: the main factory does not open until mid-2026, no paying customers have been named publicly, and no independent scientist has confirmed the scientific claims work. The race is against giants like DeepMind, Microsoft, and well-funded startups like Ginkgo and Periodic Labs that are pursuing nearly identical strategies with larger budgets. What changes the picture: whether the robot factory actually runs well and produces real scientific breakthroughs or named customers within the next year before the money runs out or rivals ship their own wins.

Why

AI pressure: Periodic Labs. Ex-OpenAI and DeepMind researchers raised $605M to run the same closed-loop lab-plus-model playbook, no product live yet. Could AI do the core job? Only partly.

Bigger players: Isomorphic Labs (Alphabet) and NVIDIA/Eli Lilly co-innovation lab. Isomorphic already has paid deals with Lilly and Novartis; NVIDIA and Lilly opened a $1B lab in Jan 2026 while Lila has no named customers. Could a giant copy it? Yes, easily.

What protects it. $550M raised plus Flagship Pioneering's team and lab-build experience buys time to finish the factory before rivals prove out results.

What would change this call

Lila's Series B closes (or fails to close) at reported ~$8.5B pre-money terms. Shows whether investor demand matches the hype or the round gets repriced down.
A named marquee pharma customer with disclosed contract value appears within 12 months. Would prove commercial traction exists beyond funding announcements.
Isomorphic Labs, Periodic Labs, or the NVIDIA/Lilly co-lab announces a validated discovery first. Would show a better-funded or better-pedigreed rival reaching proof before Lila does.

Key numbers

$550M total raised, valuation over $1.3B (2025-10-09)
Series B talks at ~$8.5B pre-money value (2026-06-03)
Zero named commercial customers since Oct 2025 onboarding claim (2026-06-03)

Named risks

No independently validated scientific results despite claims of novel antibodies, catalysts, materials as of July 2026. Severity: high
No named paying customers disclosed despite onboarding a first cohort since October 2025. Severity: high
Flagship 200,000 sq ft AI Science Factory not yet operational, only targeted for Q3 2026. Severity: medium
Conflicting reports on Series B status, Bloomberg says in talks while Caplight lists round as closed at $10.5B, June 3 2026. Severity: medium
Multiple well-funded rivals (Periodic Labs $605M, Isomorphic Labs, NVIDIA-Lilly lab) running near-identical playbooks with no structural bar to entry. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Periodic Labs	contesting	Ex-OpenAI/DeepMind founders raised $605M for autonomous-lab science, per report dated 2026-06-11
Isomorphic Labs (Alphabet/DeepMind)	contesting	AI-driven drug discovery spinout listed as top adjacent rival, capital scale far exceeds Lila's $550M
Ginkgo Bioworks	contesting	Incumbent biofoundry model contrasted directly against Lila's closed-loop approach, analysis dated 2026-03-11
NVIDIA/Eli Lilly co-innovation lab	contesting	~$1B AI drug-discovery lab using BioNeMo announced January 12, 2026
Radical AI	contesting	Pursuing near-identical full-stack autonomous-lab approach with early defense traction, per 2026-06-11 report

Questions people ask

Is Lila Sciences profitable in 2026?: Lila Sciences discloses no revenue figures. As of October 2025 it had raised $550M total and was valued above $1.3B, and it says it began onboarding an undisclosed first cohort of commercial partners that month, but no paying customers have been named as of July 2026.
Who owns Lila Sciences?: Lila Sciences is privately held, founded in 2023 inside Flagship Pioneering, the venture-creation firm behind Moderna, which remains an investor. It publicly unveiled from stealth on March 10, 2025 with a $200M seed round led by Flagship Pioneering.
Could AI replace what Lila Sciences does?: Lila Sciences is itself the AI disruptor, not a target: its business model bets that AI agents plus robotic labs can replace human-driven hypothesis generation and experimentation, a shift it calls a 'Deep Blue moment' for science, per its own June 2026 team commentary.
Is joining Lila Sciences a safe career move?: Lila Sciences has raised $550M as of October 2025 at a valuation above $1.3B and was reportedly in talks for a ~$2B Series B as of June 3, 2026, but it has no named customers, no confirmed revenue, and its flagship factory is still targeted to open Q3 2026, making it a high-upside, high-uncertainty bet.
Who is Lila Sciences' biggest competitor?: Lila Sciences faces well-funded rivals running near-identical playbooks: Periodic Labs, founded by ex-OpenAI and DeepMind researchers, had raised $605M as of June 11, 2026, while Isomorphic Labs (Alphabet/DeepMind) and Ginkgo Bioworks compete in adjacent autonomous-lab and drug-discovery models.
Has Lila Sciences raised a Series B?: As of June 3, 2026, Bloomberg reported Lila Sciences was in talks for a roughly $2B Series B anchored by CalPERS and Nvidia's NVentures at about $8.5B pre-money valuation, but terms were not final and no primary Lila press release confirming a closed round existed as of July 29, 2026.

Timeline

2026-06-22Lila Sciences announces integration with NVIDIA's BioNeMo Agent Toolkit for biological AI agents
2026-06-03Bloomberg reports Lila in talks for ~$2B Series B at ~$8.5B pre-money, ~$10.5B post-money
2026-05-23Lila Sciences named #25 on CNBC's 2026 Disruptor 50 list
2026-01-12Lila named ecosystem partner at NVIDIA BioNeMo launch, JPM Healthcare Conference
2025-10-09$115M Series A extension closes, bringing total raised to $550M, valuation above $1.3B
2025-10-02Lila says it begins onboarding first cohort of commercial partners, none named
2025-09-15Lila closes $235M Series A first tranche co-led by Braidwell and Collective Global
2025-06Lila commits to adding 100+ Massachusetts life-sciences roles under state tax incentive
2025-03-10Lila Sciences unveiled from stealth by Flagship Pioneering with $200M committed seed

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.